✦ LIBER ✦

A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illness

✍ Scribed by Trevor R. Norman; David Ames; Graham D. Burrows; Brian Davies

Book ID: 118388438
Publisher: Elsevier Science
Year: 1985
Tongue: English
Weight: 535 KB
Volume: 8
Category: Article
ISSN: 0165-0327
DOI: 10.1016/0165-0327(85)90069-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiocirculatory effects of moclobemide

Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential Type A inhibition, in healthy volunteers and depressive patients

✍ S. Gasic; A. Korn; H. G. Eichler; I. Oberhummer; H. G. Zapotoczky 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 380 KB

A Canadian multicentre placebo-controlle

A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression

✍ G. Chouinard; B.M. Saxena; N.P.V. Nair; S.P. Kutcher; D. Bakish; J. Bradwejn; S. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 920 KB

Cianopramine and amitriptyline in the tr

Cianopramine and amitriptyline in the treatment of depressed patients — a placebo-controlled study

✍ L. Hormazabal; L. M. O. Omer; S. Ismail 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 330 KB

3-Cyano-imipramine (cianopramine) is a potent and selective inhibitor of serotonin uptake into synaptosomes. In a double-blind trial, 60 patients with various types of depression fulfilling the DSM-III criteria of depressive episodes were treated with either cianopramine (n=20, mean daily dose 3.3\_

Early experience with CGP 4718 A (Serclo

Early experience with CGP 4718 A (Sercloremine), a new selective and reversible MAO-A and 5-HT-uptake inhibitor, in the treatment of depressive patients

✍ A. Delini-Stula; R. Fischbach; F. Gnirss; E. Bures; W. Pöldinger 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 654 KB

A double-blind randomized placebo-contro

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression

✍ J. E. De Wilde; S. Geerts; J. Van Dorpe; J. Bruhwyler; J. Géczy 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 674 KB

Double-Blind Randomized Controlled Pilot

Double-Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression

✍ J. DE WILDE; C. MERTENS; J. VAN DORPE; J. BRUHWYLER; J. GÉCZY 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

This double-blind randomized pilot study aimed to compare the ecacy and the tolerability of pirlindole (150±225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60±90 mg/day) in the treatment of major depression. Forty patients were included in the trial (20 pirlindole and 20 m